Topical XXXX 1% for the Treatment of @entity102 .

@entity1 @entity9472 @entity32 @entity146 @entity102 @entity205
OBJECTIVE: To evaluate the use of topical @entity205 ( @entity9472 ) 1% in the treatment of @entity102 ( @entity102 ). METHODS: Retrospective chart review from 2001 to 2012 identified 12 @entity1 (22 eyes) with @entity102 (mean  standard deviation [SD] age, 50.2  15.4 years; 75% female; 92% white) treated with @entity9472 . Main outcome measures included @entity32 grade, visual acuity, concurrent corticosteroid (CS) therapy, effect on CS taper, and adverse effects. RESULTS: Mean  SD follow-up time was 11.7  9.7 months. Mean  SD time from diagnosis to @entity9472 treatment initiation was 2.4  3.2 months. Mean  SD duration of @entity9472 treatment was 5.8  2.8 months. Four @entity1 (33%) complained of @entity146 (n=2), redness (n=1), itching (n=1), and burning (n=1) but none discontinued treatment. Concurrent CSs were tapered off in all @entity1 after a mean  SD of 5.0  2.5 weeks. Mean  SD initial vision was 0.078  0.093 logMAR, whereas vision at final examination was 0.056  0.081 logMAR (P=0.02). Mean  SD initial @entity32 grade of 1.9  1.0 was significantly reduced to final grade of 0.7  0.9 (P=0.0002). Mean  SD time to initial @entity32 control in 9 @entity1 (75%) was 33.2  24.5 days. Two @entity1 (17%) switched to oral @entity9472 because of lack of @entity32 control. CONCLUSIONS: Topical @entity9472 1% is an effective and well-tolerated therapy that @entity32 and tapered topical CS in @entity1 with @entity102 . The use of @entity9472 in such @entity1 warrants further investigation.
